Research Lends Support To Xarelto Lawsuit Claims

July 02, 2016 – – TheProductLawyers.com offers insight on the latest scholarly findings associated with the new-generation anticoagulant Xarelto, and the ongoing cases against the manufacturers, Bayer AG, and Janssen Pharmaceuticals. These findings appear to lend support to the claims that the new-generation anticoagulant is associated with significantly elevated risks of catastrophic gastrointestinal and eye bleeding events.

The first study was published in the British Medical Journal (BMJ) in April of 2015. The authors reviewed nearly 46,000 individual medical histories of those who had both a history of more traditional blood thinner use and also elected to switch to Xarelto after its introduction to the market. The researchers indicated that they found evidence of a nearly doubled risk for gastrointestinal bleeding in those who switched to the new-generation drug after using warfarin, a more traditional form of anticoagulant.

Another study was published in the June 2015 issue of JAMA Ophthalmology. Drs. Judy Hun and John C. Hwang observed patients from their joint practice that ranged from 70 to 89 in age and were currently using anticoagulants as prescribed. Many of these had a history of using warfarin but elected to taper off the drug and replace it with Xarelto after it received FDA approval in 2011.

Especially in patients who had previously taken warfarin, the doctors noted an elevated incidence of vitreous hemorrhages or eye bleeds that appeared to be connected to the shift in drug regimens. They reported the entirety of their findings to JAMA and observed, “In all cases, an acute vitreous hemorrhage occurred shortly after rivaroxaban (Xarelto) treatment was initiated.” While this appears to be a clear link between the drug and the injury, there is still much work to be done to establish the precise nature of the relationship.

What is unambiguous is the 2,800 individual cases brought against Xarelto. Late last year, these lawsuits were combined to form the multidistrict litigation (MDL) No. 2592 in order to expedite the legal process. The cases have many allegations in common, which include a substantially increased risk of catastrophic bleeding events in the eye or the gastrointestinal system, and harm as a result of such events, which may even include death. Judge Eldon Fallon will preside over the MDL in the Eastern District of Louisiana.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011137